Last reviewed · How we verify
NCT05136703: TRIDENT
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
NA trial testing Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD) in Depression in 150 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Florida International University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | other |
| Enrollment | 150 |
| Start date | 30 August 2022 |
| Primary completion | 30 June 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)
- Antiretroviral Therapy (ART) Adherence Counseling
Conditions studied
- Depression — all drugs for Depression →
- HIV-1-infection — all drugs for HIV-1-infection →
- Inflammation — all drugs for Inflammation →
Sponsor
Florida International University
Who can join
18 and older, any sex, with Depression or HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this randomized controlled trial is to understand how a cognitive-behavioral treatment (a form of psychological treatment) for depression changes the gut microbiome (micro-organisms that regulate the health of the gut), immune system, and the brain functioning in people living with HIV.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05136703
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other Florida International University trials
Trials by the same sponsor.
- NCT06965712 — Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF ) · NA · recruiting
- NCT06489314 — Mental Health Treatment to Improve Father Depression and Child Outcomes in Kenya · NA · enrolling by invitation
- NCT07199361 — Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation · NA · recruiting
- NCT04571502 — Integration of Health Information Technology and Promotion of Personhood in Family-Centered Dementia Care · NA · enrolling by invitation
- NCT06637436 — PrEP Readiness Interventions for Sustained Motivation (PRISM) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05136703 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Florida International University
- Last refreshed: 6 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05136703.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing